Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Higher costs for electromedical cos from RoHS recast

This article was originally published in Clinica

Executive Summary

Compliance with new requirements for medical devices in the context of the soon-to-be recast European Commission Directive on the Restriction of Hazardous Substances (RoHS) is going to result in higher costs for some medical device manufacturers who produce complex products in low numbers which have critical applications. That is the view of the Commission in an update just posted on its Europa website.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel